Pembrolizumab recommended for colorectal cancer patients with rare mutations

NICE's draft guidance recommends that treatment with pembrolizumab is stopped at 2 years if there is no evidence that a person’s disease has got worse.

Join OnMedica and benefit from:

  • Bitesize CPD and easy to digest content, free for UK-based GPs and specialist doctors
  • High-quality, evidence-based content developed by expert editors and clinicians
  • Articles, quizzes, videos, visual summaries and more
  • Regulatory alerts and round-up of medical journals
  • New content added daily, so you know you’re always up to date

Existing members Sign in